Table 2 Peak vasoactive medication dosing in first 24 h
From: Development and performance of a novel vasopressor-driven mortality prediction model in septic shock
Vasoactive medication | Total cohort (n = 5352) | Derivation cohort (n = 4033) | Validation cohort (n = 1319) | p |
|---|---|---|---|---|
Vasopressin | ||||
Total patients | 2200 (41.1) | 1644 (40.8) | 556 (42.2) | 0.38 |
Peak dose (U/min) | 0.04 (0.04–0.04) | 0.04 (0.04–0.04) | 0.04 (0.04–0.04) | 0.98 |
Epinephrine | ||||
Total patients | 1633 (30.5) | 1207 (29.9) | 426 (32.3) | 0.11 |
Peak dose (mcg/kg/min) | 0.05 (0.04–0.1) | 0.05 (0.04–0.1) | 0.05 (0.04–0.1) | 0.47 |
Phenylephrine | ||||
Total patients | 355 (6.6) | 280 (6.9) | 75 (5.7) | 0.13 |
Peak dose (mcg/kg/min) | 0.6 (0.1–1.3) | 0.6 (0.3–1.2) | 0.8 (0.4–1.4) | 0.10 |
Dobutamine | ||||
Total patients | 271 (5.1) | 201 (5.0) | 70 (5.3) | 0.66 |
Peak dose (mcg/kg/min) | 5 (5–10) | 5 (5–10) | 5 (5–7.5) | 0.38 |
Dopamine | ||||
Total patients | 208 (3.9) | 150 (3.7) | 58 (4.4) | 0.29 |
Peak dose (mcg/kg/min) | 5 (3–10) | 5 (3–10) | 5 (3–13) | 0.29 |
Milrinone | ||||
Total patients | 700 (13.1) | 522 (12.9) | 178 (13.5) | 0.61 |
Peak dose (mcg/kg/min) | 0.25 (0.25–0.37) | 0.25 (0.25–0.38) | 0.25 (0.2–0.3) | 0.12 |